Overcoming Nonclinical and Clinical Immunogenicity Assessment Challenges
Are you facing challenges in validating immunogenicity assays required for your drug development program?
In this edition of The Altascientist, learn about the different purposes and challenges of validating immunogenicity assays to strategically develop a safe and quick approach to support nonclinical and clinical studies.
Have questions? Consult with one of our experts.
You may also be interested in these scientific posters presented at the 15th WRIB (Workshops on Recent Issues in Bioanalysis):
- Dual Purpose of a Cell-Based Assay for an Agonist of the GLP-2 Receptor
- Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response
- Development of an Oligonucleotide Drug Immunogenicity Assay: A Case for the Characterization of the Immune Response Using an Anti-Drug-Antibody Screening Assay to Resolve Selectivity Issues in Toxicokinetic Ligand-Binding Assays
Altasciences is at the forefront of microsampling, leveraging innovative technology that allows for significantly reduced blood volumes to be taken from study participants. Our fully customizable bioanalytical solutions are available as stand-alone or as part of a complete drug development program.